WASHINGTON--(BUSINESS WIRE)-- In response to a study released last week from the National Bureau of Economic Research titled “Unveiling the Mystery of Online Pharmacies: an Audit Study,” Lee Graczyk, lead organizer of RxRights, issued the following statement:
“We are pleased this authoritative study confirms what we have known all along: personal drug importation through legitimate Canadian and other international online pharmacies is a safe, money-saving option for Americans.
“More than a million Americans — and I am one of them — import prescription drugs each year. Some do so because they cannot afford the same brand-name medications that are sold in the U.S. Others import drugs because they refuse to pay the exorbitant costs of prescription medications when there is a more economical way that is just as safe.
“According to this study, among the verified websites tested, U.S.-based pharmacies charged an average of 52.5 percent more than international pharmacies for four top-selling brand-name medications.
“This study also reinforces the fact that licensed pharmacies accredited by the Canadian International Pharmacy Association (CIPA) and PharmacyChecker.com deliver drugs that are safe and authentic. These pharmacies follow stringent standards to ensure patient safety, which include requiring a valid doctor’s prescription, obtaining demographic and medical information from the patient, having a licensed pharmacist on staff, and having a physician review patient information before authorizing a prescription.
“I encourage consumers to visit www.RxRights.org to learn about finding a legitimate online pharmacy and protecting their right to access safe, affordable medications.”
RxRights is a national coalition of individuals and organizations concerned with the high cost of prescription drugs in the U.S. For more information, visit www.RxRights.org.
Lee Graczyk, 1-866-703-5442
KEYWORDS: United States North America Canada District of Columbia
INDUSTRY KEYWORDS: Seniors Technology Online Retail Internet Health Public Policy/Government Healthcare Reform Pharmaceutical Other Government Public Policy Professional Services Insurance Retail Consumer General Health